Palliative Reconstruction for the Management of Incurable Head and Neck Cancer

Abstract

Background Surgical management of head and neck cancer is resource intensive and physiologically demanding. In patients with incurable disease, although the indications for surgery are not well defined, palliative benefit can be significant. The goal of this investigation was to compare outcomes of patients who underwent resection and reconstruction of head and neck cancer with curative intent with those who underwent similar procedures with palliative intent.

Methods A retrospective review of patients who underwent reconstruction for head and neck cancer between 2008 and 2014 was conducted. Patients were divided into curative and palliative groups. Outcomes assessed included postoperative complications and survival.

Results A total of 147 patients who underwent 156 operations met inclusion criteria (27 palliative and 129 curative). In both cohorts, the most common histology was squamous cell carcinoma (SCC) and the most common primary tumor site was the oral cavity. There was no significant difference between the cohorts in the rates of systemic and reconstructive complications, postoperative hospital length of stay, 30-day mortality, and flap survival. Overall survival in palliative patients was significantly shorter compared with curative patients (median OS, 6.2 months vs. 56.1 months, respectively; p < 0.0001). Among patients undergoing palliative surgery, patients without carotid involvement and those with non-SCC were significantly more likely to have longer survival.

Conclusion Surgical resection with reconstruction is possible in head and neck oncologic patients undergoing palliative treatment. Palliative patients have similar short-term outcomes when compared with patients undergoing resection for curative intent. Quality-of-life and economic implications of these approaches deserve closer scrutiny.

Keywords

palliative surgery - head and neck reconstruction - head and neck cancer - palliative reconstruction

• References

• 1 Ferlay J, Soerjomataram I, Ervik M , et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. Available at: http://globocan.iarc.fr ; Accessed September 7, 2014
• 2 Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61 (2) 69-90
• 3 Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014; 64 (1) 9-29
• 4 Datema FR, Ferrier MB, van der Schroeff MP, Baatenburg de Jong RJ. Impact of comorbidity on short-term mortality and overall survival of head and neck cancer patients. Head Neck 2010; 32 (6) 728-736
• 5 Vermorken JB, Specenier P. Optimal treatment for recurrent/metastatic head and neck cancer. Ann Oncol 2010; 21 (7) (Suppl. 07) vii252-vii261
• 6 Gregoire V, Lefebvre JL, Licitra L, Felip E ; EHNS-ESMO-ESTRO Guidelines Working Group. Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21 (5) 184-186
• 7 Vermorken JB, Remenar E, van Herpen C , et al; EORTC 24971/TAX 323 Study Group. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 2007; 357 (17) 1695-1704
• 8 Marur S, Forastiere AA. Head and neck cancer: changing epidemiology, diagnosis, and treatment. Mayo Clin Proc 2008; 83 (4) 489-501
• 9 Posner MR, Hershock DM, Blajman CR , et al; TAX 324 Study Group. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 2007; 357 (17) 1705-1715
• 10 Roland NJ, Bradley PJ. The role of surgery in the palliation of head and neck cancer. Curr Opin Otolaryngol Head Neck Surg 2014; 22 (2) 101-108
• 11 Takes RP, Rinaldo A, Silver CE , et al. Distant metastases from head and neck squamous cell carcinoma. Part I. Basic aspects. Oral Oncol 2012; 48 (9) 775-779
• 12 Haigentz Jr M, Hartl DM, Silver CE , et al. Distant metastases from head and neck squamous cell carcinoma. Part III. Treatment. Oral Oncol 2012; 48 (9) 787-793
• 13 Goldstein NE, Genden E, Morrison RS. Palliative care for patients with head and neck cancer: “I would like a quick return to a normal lifestyle”. JAMA 2008; 299 (15) 1818-1825
• 14 Machiels JP, Lambrecht M, Hanin FX , et al. Advances in the management of squamous cell carcinoma of the head and neck. F1000Prime Rep 2014; 6: 44
• 15 Jang DW, Teng MS, Ojo B, Genden EM. Palliative surgery for head and neck cancer with extensive skin involvement. Laryngoscope 2013; 123 (5) 1173-1177
• 16 Rodrigo JP, Kowalski LP, Silver CE , et al. When is reoperative surgery not indicated for recurrent head and neck squamous cell carcinoma?. Eur Arch Otorhinolaryngol 2015; 272 (2) 259-262
• 17 Manzoor NF, Russell JO, Bricker A , et al. Impact of surgical resection on survival in patients with advanced head and neck cancer involving the carotid artery. JAMA Otolaryngol Head Neck Surg 2013; 139 (11) 1219-1225
• 18 Ozer E, Agrawal A, Ozer HG, Schuller DE. The impact of surgery in the management of the head and neck carcinoma involving the carotid artery. Laryngoscope 2008; 118 (10) 1771-1774
• 19 Hartl DM, Brasnu DF, Shah JP , et al. Is open surgery for head and neck cancers truly declining?. Eur Arch Otorhinolaryngol 2013; 270 (11) 2793-2802
• 20 Chan JY, To VS, Wong ST, Wei WI. Quality of dying in head and neck cancer patients: the role of surgical palliation. Eur Arch Otorhinolaryngol 2013; 270 (2) 681-688
• 21 Ledeboer QC, van der Schroeff MP, Pruyn JF, de Boer MF, Baatenburg de Jong RJ, van der Velden LA. Survival of patients with palliative head and neck cancer. Head Neck 2011; 33 (7) 1021-1026